CST-2140 by CuraSen Therapeutics for Orthostatic Hypotension: Likelihood of Approval

CST-2140 is under clinical development by CuraSen Therapeutics and currently in Phase I for Orthostatic Hypotension.

Synthetic mucins shed light on cancer biology and tumor formation

During cold and flu season, excess mucus is a common, unpleasant symptom of illness, but the slippery substance is essential to human health.

March 18, 2024

For clinician-administered drugs, researchers find no association between price increases and OOP cost increases

It seems obvious to assume that patient out-of-pocket costs would increase as drug companies raise the prices of their drugs. But a new study published

January 23, 2024

How A Human-AI Partnership Can Boost Clinical Trial Recruitment

The demand for clinical trial testing is rising, from over 260,000 trials conducted in 2018 to nearly double that figure in 2024. This means that more trials are being conducted

October 23, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.